Zoloft patent extension part of debate over antidepressants for children

[Guest guest]

Zoloft patent extension part of debate over antidepressants for children

Pfizer's success in getting Zoloft's patent extended resulted in part to

turning two failed pediatric clinical trials into a positive study that is

part of the current debate over suicidal risks connected to antidepressant

use by children. A pair of pediatric trials conducted as a condition of the

extension concluded Zoloft was no more efficacious than a placebo, but the

trial results were never published or released to the public. A subsequent

journal article based on the unpublished studies said Zoloft was effective

for children, and now Pfizer is one of several makers that could face legal

action. The Wall Street Journal

http://rdr.sbml.cc/Click?q=59-y52oIEn5hMykg3YlpQ8ZlKwjddRR (subscription

required) (8/6)